Clinical Results Presented at the Southeastern Section of the American Urological Association Confirms HIFU's Safety, Efficacy and Benefits for Patients' Quality Of Life LYON, FRANCE , AUSTIN, TX -- APRIL 3, 2018 - EDAP TMS (Nasdaq: EDAP) today announced that preliminary results of the first U.S.

LYON, France , May 2, 2018 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the first quarter ended March 31, 2018 , after the close of the financial markets on Monday, May 14, 2018 .

2018 Q1 total revenue records a 6% increase year-over-year Focal One Final Additional Information submitted to FDA early May EDAP to attend American Urological Association congress in San Francisco , May 18-21, 2018 LYON, France , May 14, 2018 -- EDAP TMS SA (Nasdaq: EDAP) ("the Company"), the

AUSTIN, TX , LYON, FRANCE -- JUNE 7, 2018 -- EDAP TMS SA (Nasdaq: EDAP) ("the Company"), the global leader in therapeutic ultrasound, today announced that it has received 510(k) clearance from the US Food and Drug Administration ( FDA ) for its Focal One device for the ablation of prostate tissue. 

LYON, France , July 24, 2018 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the second quarter and six months ended June 30, 2018 , before the open of the financial markets on Thursday, August 30, 2018 .

Receives FDA clearance for novel Focal One device for prostate tissue ablation LYON, France , August 29, 2018 -- EDAP TMS SA (Nasdaq: EDAP) ("the Company"), the global leader in therapeutic ultrasound, announced today financial results for the second quarter of 2018 and provided a strategic and

Successful HIFU Treatments Performed in Seoul National University Bundang Hospital LYON, France , September 20, 2018 -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the installation of the first Focal One device in South Korea , at the renowned Seoul

AUSTIN, TX - LYON, France , September 26, 2018 - EDAP TMS (Nasdaq: EDAP) today announced the results of a study conducted at Houston Methodist Medical Center in Houston, TX that showed High Intensity Focused Ultrasound (HIFU) to be safe and effective, with oncologic control for prostate cancer

HIFU Prostate Cancer Treatments Successfully Performed at Albert Einstein Hospital , Sao Paulo LYON, France , September 27, 2018 -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the installation of the third Focal One device in Brazil at the renowned Albert

   Warrants for Approximately 3.3 Million Ordinary Shares in the Form of American Depository Shares Expired on October 14, 2018 LYON, France , October 15, 2018 -- EDAP TMS SA (Nasdaq: EDAP) ("the Company"), the global leader in therapeutic ultrasound, announced today that warrants for approximately